Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Immune cell clues could forecast Crohn's relapse after surgery

NCT ID NCT02770495

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 59 adults with Crohn's disease who had surgery to remove diseased parts of their intestine. The goal was to see if certain immune cells in the blood and gut could predict whether the disease would come back within a year. By understanding these patterns, doctors hope to identify high-risk patients earlier and develop better treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

59 people

The number who actually took part.

Start date

Jan 2011

Finished

Apr 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged over 18 years * Men or non-pregnant women * Patients with a diagnosis of Crohn's disease who undergo an ileo-colonic curative resection * No change of the postoperative treatment before assessing an endoscopic recurrence during the one-year post surgery follow-up period * Informed consent given Exclusion Criteria: * Pregnancy * History of disease, including mental/emotional disorder, that might interfere with their participation in the study * Inability to comply with the protocol requirements * Inability to fill in the diary cards

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Service d'Hépato-Gastroentérologie Centre hospitalier Lyon Sud Hospices Civils de Lyon

    Pierre-Bénite, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.